Clinical and Disease Characteristics From REVEAL at Time of Enrollment (Baseline): Prospective Observational Study of Patients With Polycythemia Vera in the United States
Michael R. Grunwald(Levine Cancer Institute), Ruben A. Mesa(Atrium Health Wake Forest Baptist), Shreekant Parasuraman(Incyte (United States)), Philomena Colucci(Incyte (United States)), Dilan Paranagama(Incyte (United States)), Stephen T. Oh(Washington University in St. Louis), Ralph V. Boccia(Center for Cancer and Blood Disorders), Brady L. Stein(Barnes-Jewish Hospital)
Cited by 37
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia
|Science Translational Medicine|2016|916
<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
|New England Journal of Medicine|2016|783
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761